Announcement PDF Neuren (NEU) – ASX Announcement 29 February 2024 Neuren 2023 results investor webinar on 29 February 2024 Investor Webinar 16:30 AEDT Thursday 29 February 2024 You are invited to register using this link: https://us06web.zoom.us/webinar/register/WN_z8twoNnaSPugJPE5eAousQ Participants may submit questions at registration or during the session Thursday 29 February 2024, Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU), following confirmation yesterday of the DAYBUE™(trofinetide) royalty in Q4 2023 for inclusion in its audited financial statements, will report its full-year 2023 financial results today and Neuren’s management will host an investor webinar at 16:30 Australian Eastern Daylight Time to discuss the results. Registration for the webinar may be completed via the link above. About Neuren Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. Contact: Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271 ASX Listing Rules information This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 Forward-looking Statements This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement. 1 of 1